|
|
|
|
| Multispecific molecules bring added complexity to downstream purification—think incorrect chain pairings, aggregation, fragmentation, and lower yields. Join Bioprocess Online Live as we explore how developers are addressing these challenges to achieve high purity and efficient processes. Gain insights into key considerations for downstream teams when designing purification strategies for these advanced biologics. Registration is free thanks to the support of Thermo Fisher Scientific. |
|
|
|
|
By Nero Haralalka, TBM Consulting Group | The U.S. tariffs on trading partners bring a whole new set of challenges, but there are tactics and strategies companies can deploy to help offset the cost and operational impacts. | |
|
|
| Why CDMOs Benefit From Digitalization | Article | Koerber Pharma | Discover why digitization is crucial for cell and gene contract manufacturers by learning the various benefits digital transformation can offer such as efficiency, compliance, and innovation. |
|
|
| Viral Vector Manufacturing: A Case For Adherent Cell Culture | Q&A | By Junwei Sun, Dr. Lucia Fernandez and Matthew Ercolino, VintaBio | Review the importance of alternative approaches to viral vector production and the benefits of intensified adherent cell culture for improving efficiency, reducing costs, and accelerating development. |
|
|
| Optimizing Reference Standards For Your Biopharmaceutical | White Paper | Labcorp Biopharmaceutical CMC Services | By addressing considerations for a comprehensive reference standard strategy, manufacturers can ensure the integrity of biopharmaceuticals, ultimately paving the way for better patient outcomes. |
|
|
|
| Accelerate And De-Risk Bioconjugate Drug Development | Article | By Elisabeth Engelsberger, Ph.D. and Raphael Frey, Ph.D., Lonza | With a growing interest in developing new and improved bioconjugate drugs, explore an “innovation through collaboration” approach that can facilitate access to next-generation conjugation technologies. |
|
|
|
| The Challenges Of Moving A Bioconjugate From Clinic To Market | Article | By Iwan Bertholjotti and Dr. Bernhard Stump, Lonza | Working with a partner that provides a one-stop shop for bioconjugate development and manufacturing helps prevent missteps that threaten the delivery of life-saving drugs to patients who need them. |
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
